This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Pharmacoeconomic review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Pharmacoeconomic Review Report; SR0356. 2014
The ICURs of sofosbuvir versus appropriate comparators varied widely across genotypes and various subgroups. Analyses in genotype 1 patients were limited by lack of direct comparative data. Most of the analyses in genotype 2 and genotype 3 patients were limited by the small sample size of the clinical trials used to inform efficacy inputs. Based on CDR reanalyses, sofosbuvir is likely cost-effective in the following subgroups: genotype 1 treatment-naive cirrhotic patients (compared with boceprevir and Peg-INF/RBV, but analyses were based on very small subgroups, and on a naive indirect treatment comparison); genotype 2 Peg-INF/RBV-ineligible and prior-relapsers or breakthrough (except cirrhotic patients) compared with no treatment and Peg-INF/RBV; genotype 3 prior-relapsers or breakthrough with cirrhosis, compared with no treatment and Peg-INF/RBV.
Subject indexing assigned by CRD
Antiviral Agents; Hepatitis C, Chronic; Humans; Uridine Monophosphate
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: email@example.com
Date abstract record published